Transcriptional regulation of ubiquitin specific peptidase 2b by farnesoid X receptor and its implications in the pathogenesis of hepatocellular carcinoma.
Winifer Ali, Christina Nadolny, Xinmu Zhang, Qiwen Chen, Syed F Hashmi, Tasneem Huniti, Md Mosiqur Rahman, Lia Bozza, Danielle Warila, Ruitang Deng
{"title":"Transcriptional regulation of ubiquitin specific peptidase 2b by farnesoid X receptor and its implications in the pathogenesis of hepatocellular carcinoma.","authors":"Winifer Ali, Christina Nadolny, Xinmu Zhang, Qiwen Chen, Syed F Hashmi, Tasneem Huniti, Md Mosiqur Rahman, Lia Bozza, Danielle Warila, Ruitang Deng","doi":"10.62347/UIYZ8333","DOIUrl":null,"url":null,"abstract":"<p><p>Farnesoid X receptor (FXR) signaling plays an important role in liver regeneration and carcinogenesis. Dysregulation of FXR signaling is linked to the pathogenesis of hepatocellular carcinoma (HCC) while FXR knockout mice spontaneously develop HCC as they age. Ubiquitin specific peptidase 2b (USP2b) is a deubiquitinating enzyme regulating protein stability and other activities. In our recent study, we found that USP2b was significantly downregulated in subjects with HCC and exhibited both tumor-promoting and tumor suppressive activity in a context-dependent manner. However, the mechanistic link between FXR signaling and USP2b and its implications in the pathogenesis of HCC remain to be determined. In this study, we revealed that USP2b was transcriptionally regulated by FXR. Activation of FXR significantly increased while antagonizing FXR reduced USP2b mRNA and protein expression <i>in vitro</i> and <i>in vivo</i>. Consistently, USP2b expression was significantly reduced in FXR knockout (FXR-KO) mice. Further investigation showed that USP2b was transcriptionally regulated by FXR in an isoform-specific manner, predominantly by FXRα2 but not FXRα1. The transcription starting sites (TSS) of USP2 isoforms were determined by 5'RACE, which leads to the identification of the USP2b-specific promoter. An FXR response element (FXRE) was identified in the USP2b promoter and functionally characterized. FXR directly bound to the FXRE <i>in vitro</i> and recruited to the USP2b promoter in intact cells and <i>in vivo</i>. Further study revealed that upon FXR activation, co-activator-associated arginine methyltransferase 1 (CARM-1) was significantly recruited to the human USP2b promoter while coactivators glutamate receptor-interacting protein 1 (GRIP-1) and peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) were significantly recruited to the mouse USP2b promoter. Over-expression of USP2b in FXR-KO mice significantly slowed down tumor growth with reduced tumor size while maintained comparable tumor numbers consistent with its tumor suppressive activity. In summary, this study demonstrated that USP2b was transcriptionally regulated by FXR in an isoform-dependent manner and USP2b played a tumor-suppressive role in the pathogenesis of FXR deficiency-induced HCC.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"16 8","pages":"3660-3677"},"PeriodicalIF":3.1000,"publicationDate":"2026-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559341/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/UIYZ8333","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Farnesoid X receptor (FXR) signaling plays an important role in liver regeneration and carcinogenesis. Dysregulation of FXR signaling is linked to the pathogenesis of hepatocellular carcinoma (HCC) while FXR knockout mice spontaneously develop HCC as they age. Ubiquitin specific peptidase 2b (USP2b) is a deubiquitinating enzyme regulating protein stability and other activities. In our recent study, we found that USP2b was significantly downregulated in subjects with HCC and exhibited both tumor-promoting and tumor suppressive activity in a context-dependent manner. However, the mechanistic link between FXR signaling and USP2b and its implications in the pathogenesis of HCC remain to be determined. In this study, we revealed that USP2b was transcriptionally regulated by FXR. Activation of FXR significantly increased while antagonizing FXR reduced USP2b mRNA and protein expression in vitro and in vivo. Consistently, USP2b expression was significantly reduced in FXR knockout (FXR-KO) mice. Further investigation showed that USP2b was transcriptionally regulated by FXR in an isoform-specific manner, predominantly by FXRα2 but not FXRα1. The transcription starting sites (TSS) of USP2 isoforms were determined by 5'RACE, which leads to the identification of the USP2b-specific promoter. An FXR response element (FXRE) was identified in the USP2b promoter and functionally characterized. FXR directly bound to the FXRE in vitro and recruited to the USP2b promoter in intact cells and in vivo. Further study revealed that upon FXR activation, co-activator-associated arginine methyltransferase 1 (CARM-1) was significantly recruited to the human USP2b promoter while coactivators glutamate receptor-interacting protein 1 (GRIP-1) and peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α) were significantly recruited to the mouse USP2b promoter. Over-expression of USP2b in FXR-KO mice significantly slowed down tumor growth with reduced tumor size while maintained comparable tumor numbers consistent with its tumor suppressive activity. In summary, this study demonstrated that USP2b was transcriptionally regulated by FXR in an isoform-dependent manner and USP2b played a tumor-suppressive role in the pathogenesis of FXR deficiency-induced HCC.
期刊介绍:
The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.